Hatem Azim

Hatem Azim, MD, PhD is a practicing medical oncologist with extensive leadership experience in drug development in academia and biotech field. He has deep expertise in breast cancer, has authored more than 150 peer-reviewed publications, with previous appointments at leading European institutions including the Jules Bordet Institute in Brussels.

Dr. Azim has held senior industry roles, including Vice President of Clinical Development at Innate Pharma, and head of early drug development at Pierre Fabre, He also served as Chief Medical Officer at Emergence Therapeutics, acquired by Eli Lilly in 2024. He currently holds part-time Chief Medical Officer roles in several biotechnology companies, advising on clinical and translational development strategy. His work integrates clinical strategy, translational science, and execution across the drug development lifecycle in addition to leading discussions with FDA/EMA.

He holds a PhD from Université libre de Bruxelles (ULB) and remains actively engaged in clinical practice as a breast cancer oncologist, ensuring a strong connection between patient care and industry development.